Patents Assigned to Janssen Biotech, Inc.
  • Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
    Patent number: 11459391
    Abstract: The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: October 4, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Sheri Moores, Smruthi Vijayaraghavan
  • MATERIALS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
    Publication number: 20220306739
    Abstract: Anti-TRGV9 molecules, such as anti-TRGV9 antibodies or antigen binding fragments thereof, are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 29, 2022
    Applicant: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh
  • CHIMERIC ANTIGEN RECEPTOR SYSTEM AND USES THEREOF
    Publication number: 20220305056
    Abstract: Provided herein are chimeric antigen receptors (CARs), cells comprising the CARs, monoclonal and bispecific antibodies or antigen-binding fragments thereof, and kits comprising the same. The CARs and bispecific antibodies are designed to target at least one tumor antigen and at least one tumor in methods of treating cancer in subjects in need thereof.
    Type: Application
    Filed: August 26, 2020
    Publication date: September 29, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Bharathikumar Vellalore MARUTHACHALAM, Sathyadevi VENKATARAMANI, Iqbal GREWAL, Sanjaya SINGH, Paul HARVILLA, Martin Jack BORROK III, Ninkka TAMOT, Yonghai LI
  • METHODS FOR LOWERING BLOOD GLUCOSE
    Publication number: 20220296653
    Abstract: The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.
    Type: Application
    Filed: June 2, 2022
    Publication date: September 22, 2022
    Applicant: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • PD-L1 binding fibronectin type III domains
    Patent number: 11447539
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • OPTIMIZED CULTURE MEDIA FOR CLOSTRIDIA BACTERIA
    Publication number: 20220282206
    Abstract: The present invention relates to media compositions for culturing bacteria. In particular, the present invention relates to media for culture and/or fermentation of Clostridia bacteria.
    Type: Application
    Filed: July 21, 2020
    Publication date: September 8, 2022
    Applicant: Janssen Biotech, Inc.
    Inventors: John Bodek, Kristina Demjanick, Laura Grussendorf, John Jerbasi, Claus Lang, Dominik Lüthy, Peter Hebbeln
  • DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO SINGLE HORMONAL INSULIN POSITIVE CELLS
    Publication number: 20220275340
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.
    Type: Application
    Filed: May 20, 2022
    Publication date: September 1, 2022
    Applicant: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • MATERIALS AND METHODS FOR ENHANCED LINKER TARGETING
    Publication number: 20220267472
    Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.
    Type: Application
    Filed: February 15, 2022
    Publication date: August 25, 2022
    Applicant: Janssen Biotech, Inc.
    Inventors: Sanjaya SINGH, Rajkumar GANESAN, Jun CHEN, Iqbal S. GREWAL
  • MATERIALS AND METHODS FOR TARGETING REGULATORY T CELLS FOR ENHANCING IMMUNE SURVEILLANCE
    Publication number: 20220267456
    Abstract: A molecule comprising a first means of binding to a first antigen expressed on a regulatory T (Treg) cell, and a second means capable of binding to a second antigen expressed on the Treg cell, wherein the molecule is capable of inhibiting growth or proliferation of or depleting a Treg cell.
    Type: Application
    Filed: February 17, 2022
    Publication date: August 25, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Iqbal S. GREWAL, Sundee DEES, Rajkumar GANESAN, Sanjaya SINGH
  • Nucleic acids encoding anti-CD154 antibodies
    Patent number: 11421037
    Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 23, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Johan Fransson, Galina Obmolova, Anish Suri, Fang Teng, Alexey Teplyakov, Hong Zhou, Jocelyn Leu
  • Anti-CCL17 antibodies
    Patent number: 11414484
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 16, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Arthritis treatment
    Patent number: 11390672
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 19, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Differentiation of human embryonic stem cells into single hormonal insulin positive cells
    Patent number: 11377640
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: July 5, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Methods for lowering blood glucose
    Patent number: 11369642
    Abstract: The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: June 28, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Anti-PHF-tau antibodies and uses thereof
    Patent number: 11365244
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 21, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • FC engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them
    Patent number: 11359029
    Abstract: The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: June 14, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Di Zhang
  • CD137 binding fibronectin type III domains
    Patent number: 11345739
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 31, 2022
    Assignee: JANSSEN BIOTECH, INC
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Methods for Producing Anti-TNF Antibody Compositions
    Publication number: 20220153829
    Abstract: Presented here are methods for producing a recombinant anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:38 and a light chain (LC) comprising SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.
    Type: Application
    Filed: February 26, 2020
    Publication date: May 19, 2022
    Applicant: Janssen Biotech, Inc.
    Inventors: Kristopher Barnthouse, Subinay Ganguly, Maarten Groeneveld, Manuel Lopez, Michael Nedved, Kevin D. Smith
  • Manufacturing Methods for Producing Anti-TNF Antibody Compositions
    Publication number: 20220153830
    Abstract: The present invention relates to methods of manufacture for producing anti-TNF antibodies, e.g., the anti-TNF antibody a recombinant anti-TNF antibody having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.
    Type: Application
    Filed: February 26, 2020
    Publication date: May 19, 2022
    Applicant: Janssen Biotech, Inc.
    Inventors: Kristopher Barnthouse, Subinay Ganguly, Maarten Groeneveld, Manuel Lopez, Michael Nedved, Kevin D. Smith
  • Pharmaceutical package
    Patent number: D964171
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: September 20, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Cedric Gysel, Michael Cannamela, Roland Schultz, Peter Braun